|
Name |
2-Piperidin-1-yl-6,7-dihydro-oxazolo[3,2-a][1,3,5]triazin-4-one
|
Molecular Formula | C10H14N4O2 | |
IUPAC Name* |
2-piperidin-1-yl-6,7-dihydro-[1,3]oxazolo[3,2-a][1,3,5]triazin-4-one
|
|
SMILES |
C1CCN(CC1)C2=NC(=O)N3CCOC3=N2
|
|
InChI |
InChI=1S/C10H14N4O2/c15-9-11-8(13-4-2-1-3-5-13)12-10-14(9)6-7-16-10/h1-7H2
|
|
InChIKey |
JILRFEZKPWVOKX-UHFFFAOYSA-N
|
|
Synonyms |
MLS000066051; Oprea1_439539; CHEMBL1879903; HMS2273J06; ZINC528234; 2-Piperidin-1-yl-6,7-dihydro-oxazolo[3,2-a][1,3,5]triazin-4-one; STK975669; AKOS000508876; CCG-144938; SDCCGMLS-0018486.P002; SMR000079516; SR-01000538744; SR-01000538744-1; 2-(1-piperidinyl)-6,7-dihydro-4H-[1,3]oxazolo[3,2-a][1,3,5]triazin-4-one; 2-(piperidin-1-yl)-6,7-dihydro-4H-[1,3]oxazolo[3,2-a][1,3,5]triazin-4-one; 2-piperidin-1-yl-6,7-dihydro-4H-[1,3]oxazolo[3,2-a][1,3,5]triazin-4-one
|
|
CAS | NA | |
PubChem CID | 934799 | |
ChEMBL ID | CHEMBL1879903 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 222.24 | ALogp: | 0.5 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 57.5 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.689 |
Caco-2 Permeability: | -4.521 | MDCK Permeability: | 0.00001280 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.327 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.123 |
30% Bioavailability (F30%): | 0.306 |
Blood-Brain-Barrier Penetration (BBB): | 0.876 | Plasma Protein Binding (PPB): | 72.91% |
Volume Distribution (VD): | 0.956 | Fu: | 25.15% |
CYP1A2-inhibitor: | 0.656 | CYP1A2-substrate: | 0.612 |
CYP2C19-inhibitor: | 0.243 | CYP2C19-substrate: | 0.193 |
CYP2C9-inhibitor: | 0.417 | CYP2C9-substrate: | 0.229 |
CYP2D6-inhibitor: | 0.099 | CYP2D6-substrate: | 0.225 |
CYP3A4-inhibitor: | 0.044 | CYP3A4-substrate: | 0.433 |
Clearance (CL): | 4.379 | Half-life (T1/2): | 0.6 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.623 |
Drug-inuced Liver Injury (DILI): | 0.962 | AMES Toxicity: | 0.098 |
Rat Oral Acute Toxicity: | 0.013 | Maximum Recommended Daily Dose: | 0.044 |
Skin Sensitization: | 0.06 | Carcinogencity: | 0.847 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.038 |
Respiratory Toxicity: | 0.071 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001349 | 0.317 | D0Y2CJ | 0.348 | ||||
ENC005597 | 0.262 | D0P9RF | 0.270 | ||||
ENC001426 | 0.239 | D0S0AF | 0.242 | ||||
ENC001276 | 0.219 | D01AZG | 0.229 | ||||
ENC001017 | 0.213 | D0T2IA | 0.229 | ||||
ENC000579 | 0.208 | D0U2OO | 0.229 | ||||
ENC001470 | 0.202 | D0F9GE | 0.228 | ||||
ENC005003 | 0.198 | D0N3PE | 0.225 | ||||
ENC002297 | 0.198 | D0M1VC | 0.213 | ||||
ENC001712 | 0.194 | D0X0WU | 0.210 |